Journal of Diabetes Research (Jan 2024)

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

  • Gisle Langslet,
  • Thomas Nyström,
  • Dorte Vistisen,
  • Bendix Carstensen,
  • Emilie Toresson Grip,
  • Paula Casajust,
  • Giorgi Tskhvarashvili,
  • Fabian Hoti,
  • Riho Klement,
  • Kristina Karlsdotter,
  • Mikko Tuovinen,
  • Anne Pernille Ofstad,
  • Maria Lajer,
  • Christina Shay,
  • Lisette Koeneman,
  • Soulmaz Fazeli Farsani,
  • Leo Niskanen,
  • Sigrun Halvorsen

DOI
https://doi.org/10.1155/2024/6142211
Journal volume & issue
Vol. 2024

Abstract

Read online

Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.